中药联合肝动脉化疗栓塞术治疗原发性肝癌系统评价的再评价

Reevaluation of the Systematic Review of the Traditional Chinese Medicine Combined with Transarterial Chemoembolization in the Treatment of Primary Liver Cancer

目的:评价中药联合经肝动脉化疗栓塞术治疗原发性肝癌系统评价的方法学偏倚及其结论的可靠性。方法:计算机检索Cochrane图书馆、Pub Med、Guideline、中国生物医学文献数据库、中国期刊全文数据库与万方数据库,收集高质量中药联合经肝动脉化疗栓塞术治疗原发性肝癌的系统评价文献进行再评价。结果:共纳入12篇(项)系统评价。结果显示,中药联合肝动脉化疗栓塞治疗原发性肝癌可提高瘤体客观疗效、延长患者生存时间、提高生存质量,减少术后不良反应发生,且无严重中药相关不良反应报道。结论:中药联合经肝动脉化疗栓塞术治疗原发性肝癌的临床疗效显著优于单纯行经肝动脉化疗栓塞术,且安全性较好。

OBJECTIVE：To evaluate the methodological bias of systematic review and the reliability of counclusions of traditional Chinese medicine（TCM）combined with transarterial chemoembolization in the treatment of primary liver cancer,and provide evidence-based reference. METHODS：Retrieved from Cochrane Library,Pub Med,Guideline,CBM,CJFD and Wanfang Database,high quality systematic review about TCM combined with transarterial chemoembolization in the treatment of primary liver cancer was collected for reevaluation. RESULTS：Totally 12 systematic review were involved. Results showed TCM combined with transarterial chemoembolization can improve tumor’s objective response,prolong the survival time of patients,improve life quality,reduce postoperative adverse reactions with no serious adverse reactions reported related to TCM in the treatment of primary liver cancer. CONCLUSIONS：The clinical efficacy of TCM combined with transarterial chemoembolization is superior to transarterial chemoembolization alone in the treatment of primary liver cancer,with better safety.